Projects

Research

Adaption and implementation of Aboriginal child lung health tools for northern Western Australia

André Schultz MBChB, PhD, FRACP Program Head, Respiratory Health RFA Program Head, Respiratory Health RFA Prof André Schultz is the Program Head of Respiratory Health and Head of the BREATH Team at The Kids Research Institute Australia. He is

Research

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminium in Healthy Third-trimester Pregnant Women; and Safety

Elke Jennifer Peter Seppanen Kent Richmond BSc PhD RN MBBS MRCP(UK) FRACP Program Manager, Bacterial Respiratory Infectious Disease Group Clinical Research Manager Head, Vaccine Trials Group elke.seppanen@thekids.org.au Jennifer.Kent@thekids.org.au

Research

Sore Throat Melbourne and Perth Study: The Australian Strep A Vaccine Initiative (ASAVI) Urban Pharyngitis Surveillance Study (STAMPS)

Jonathan Peter Carapetis AM Richmond AM MBBS FRACP FAFPHM PhD FAHMS MBBS MRCP(UK) FRACP Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH Head, Vaccine Trials Group 08 6319 1000 contact@thekids.org.au Institute Director; Head,

Research

COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years o

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group which sits in the Wesfarmers Centre of Vaccines and Infectious Diseases. Professor Richmond is a

Research

A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine (BOOST)

Investigator: Peter Richmond Project description GSK is conducting a research study to evaluate its investigational, pentavalentmeningococcal vaccine, MenABCWY, which is based upon two licensed GSKmeningococcal vaccines, Menveo (MenACWY vaccine) and